10 results about "Viral nucleocapsid" patented technology

The invention provides a fusion protein of flounder netshell virus nucleocapsid protein, bacillus subtilis for expressing the fusion protein and an oral vaccine, and relates to the technical field of biology. According to the present invention, the sequence of the bacillus subtilis anchoring protein CotC is obtained through sequencing, the bacillus subtilis anchoring protein CotC and the flounder nested virus are fused, and after the fusion protein is introduced into the bacillus subtilis, the fusion protein can be anchored on the surface of the bacterial spore, and can be used for preparing the recombinant oral vaccine capable of being stably stored and directly fed, and a new method is developed for preventing the flounder netlike virus CSBV.

The invention belongs to the technical field of virus immunity, and particularly relates to a hantavirus nucleocapsid protein pan-MHC-I epitope peptide, a vaccine and application. The pan-MHC-I epitope peptide of the hantavirus nucleocapsid protein is at least one of amino acid sequences as shown in SEQ ID NO. 1 to SEQ ID NO. 4. The epitope peptide is used for preparing the vaccine, the immune effect of the vaccine is verified, and meanwhile, the epitope peptide is used for evaluating the effectiveness of the vaccine in the prior art. The invention clarifies the immunological characteristics of hantavirus NP antigens and the application potential of the hantavirus nucleocapsid protein pan-MHC-I epitope peptides in virus infection, disease progression and prevention. The hantavirus nucleocapsid protein pan-MHC-I epitope peptide and the corresponding vaccine are developed by using the MHC-I epitope, and CD8 + T cell response can be remarkably enhanced and activated, so that the defect of singly using the MHC-II epitope is overcome.

The invention discloses preparation of an akabane disease virus N protein monoclonal antibody and a double-antibody sandwich ELISA (Enzyme-Linked Immunosorbent Assay) detection method, in order to prepare the akabane disease virus nucleocapsid protein monoclonal antibody, an eukaryotic recombinant plasmid pFastBac-AKAV-N is constructed and is converted into a DH10bac competent cell, and a recombinant stem Bacmid-AKAV-N for expressing AKAV N is successfully obtained. After the recombinant baculovirus is transfected to an sf9 insect cell, the recombinant baculovirus capable of stably expressing the AKAV N protein is rescued. A mouse and a rabbit are immunized with the identified and purified recombinant N protein, and a monoclonal antibody and a polyclonal antibody are prepared respectively. The titer of the polyclonal antibody is measured through an ELISA method, and two positive cell strains are obtained through screening and are named as 2G4 and 6C7 respectively. Furthermore, the prepared polyclonal antibody is used as a coating antigen, an HRP-labeled 2G4 monoclonal antibody is used as a detection antibody, and a double-antibody sandwich ELISA detection method for AKAV N protein antigen detection is optimized and established. According to the method, the AKAV N antigen can be specifically recognized, and reliable technical support is provided for clinical antigen monitoring of AKAV. The monoclonal antibody preparation system and the double-antibody sandwich ELISA detection method established by the invention lay an important foundation for pathogen detection and epidemiological investigation of akabane disease.

An expression vector for producing a target protein-fused pentamer of the present invention includes a polynucleotide that encodes a pentameric toxin protein and a viral nucleocapsid as fusion partners of a target protein. In addition, a method of producing a target protein-fused pentamer of the present invention includes manufacturing an expression vector for producing a target protein-fused pentamer, which includes a polynucleotide that encodes a target protein and a pentameric toxin protein and a viral nucleocapsid as fusion partners of the target protein; producing a transformant by introducing the expression vector for producing a target protein-fused pentamer into host cells; and culturing the transformant.

Provided are compositions and methods for introducing proteins into cells. The compositions and methods relate to introducing a foreign protein as an engineered component of a paramyxovirus virus like particle (VLP). The compositions and methods pertain to modified VLPs that contain a contiguous recombinant polypeptide comprising i) all or a segment of a C-terminal domain of a paramyxovirus nucleocapsid protein and ii) a polypeptide sequence of a distinct protein that is an enzyme such as a recombinase.

An expression vector for producing target protein-fused self-assembled nanoparticles of the present invention includes a polynucleotide that encodes a crystallizable protein and a viral nucleocapsid as fusion partners of the target protein. In addition, a method of producing target protein-fused self-assembled nanoparticles of the present invention includes manufacturing an expression vector for producing target protein-fused self-assembled nanoparticles, including a polynucleotide that encodes a target protein and a crystallizable protein and a viral nucleocapsid as fusion partners of the target protein; producing a transformant by introducing the expression vector for producing target protein-fused self-assembled nanoparticles into host cells; and culturing the transformant.

The application discloses a kind of monoclonal antibody or its antigen-binding fragment of anti Oya virus nucleocapsid protein and application thereof.The monoclonal antibody F3E10 provided in the application has the characteristics such as high purity, high specificity, high affinity and high sensitivity, can specifically recognize the NP protein of OYAV, can be used as the detection antibody of Western blot and indirect immunofluorescence, is used for the qualitative detection of OYAV-NP protein and OYAV, and can realize the visualization marking and tracing of OYAV under microscope in combination with the secondary antibody labeled with fluorescence, is expected to be widely used in the research, detection and prevention and control of OYAV, and has important popularization and application value in the field of novel bunyavirus research.

A target protein expression vector of the present invention includes a polynucleotide that encodes a viral nucleocapsid as a fusion partner of a target protein. In addition, a method of producing a target protein of the present invention includes constructing a target protein expression vector, including polynucleotides encoding a target protein, and a viral nucleocapsid as a fusion partner of the target protein; preparing a transformant by introducing the target protein expression vector into a host cell; and culturing the transformant.

This invention relates to the field of biomedical technology, specifically to the application of forsythoside in the preparation of drugs for the prevention and treatment of infectious bronchitis in chickens. Immunofluorescence and Western blotting results show that forsythoside can significantly inhibit the expression of viral nucleocapsid proteins in CEK cells and reduce the viral load in CEK cells. Furthermore, forsythoside can protect against IBV infection in broiler chickens. Quantitative fluorescence results indicate a significant reduction in viral replication in the tracheal tissue of broilers. Clinical symptoms and histopathological results show that forsythoside can significantly alleviate IBV infection-induced slow weight gain, respiratory distress, and tracheal tissue damage in broilers. This invention demonstrates that forsythoside has low cytotoxicity, can effectively prevent infectious bronchitis in chickens, and has advantages such as being green and safe, leaving no residue, having few toxic side effects, and being unlikely to induce drug resistance.